These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21105130)

  • 1. Discovering neuroprotection in Parkinson's disease, or getting to haphazard.
    Kieburtz K
    Mt Sinai J Med; 2010; 77(6):700-6. PubMed ID: 21105130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in Parkinson's disease.
    Schapira AH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S41-3. PubMed ID: 20123556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective therapy for Parkinson's disease.
    Koller WC
    Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
    Hung AY; Schwarzschild MA
    Curr Opin Neurol; 2007 Aug; 20(4):477-83. PubMed ID: 17620885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evidence for disease modification in Parkinson's disease.
    Lew MF
    Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future strategies for neuroprotection in Parkinson's disease.
    Schapira AH
    Neurodegener Dis; 2010; 7(1-3):210-2. PubMed ID: 20224288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A responsive outcome for Parkinson's disease neuroprotection futility studies.
    Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K;
    Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection for Parkinson's disease.
    LeWitt PA
    J Neural Transm Suppl; 2006; (71):113-22. PubMed ID: 17447422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Apr; 15 Suppl 1():5-13. PubMed ID: 18353131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy.
    Dahodwala N; Connolly J; Farmer J; Stern MB; Jennings D; Siderowf A
    Parkinsonism Relat Disord; 2007 Dec; 13(8):495-9. PubMed ID: 17449316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection.
    Linazasoro G
    Parkinsonism Relat Disord; 2009 Jul; 15(6):401-5. PubMed ID: 19346152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.